Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world, Multicenter, 52-week Prospective Cohort Study to Capture the Reasons for Switch to Triple Combination Therapy and to Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe COPD Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece.

NCT05915182 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05915182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05915182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world, Multicenter, 52-week Prospective Cohort Study to Capture the Reasons for Switch to Triple Combination Therapy and to Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe COPD Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
July 21, 2023
Completion date
March 28, 2025
Enrollment
212 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive (copd)